Literature DB >> 7004181

Immunopathology of cardiac lesions in fatal systemic lupus erythematosus.

A K Bidani, J L Roberts, M M Schwartz, E J Lewis.   

Abstract

Immunopathologic studies were performed on cardiac tissue obtained at autopsy in 10 patients with severe systemic lupus erythematosus (SLE). The immunopathologic findings were correlated with histopathologic and clinical evidence of cardiac injury, and with clinical and serologic features of SLE. Immune reactants were demonstrated by direct immunofluorescence in nine patients in a granular deposition pattern suggesting immune complex aggregates. Histologic and gross anatomic findings of inflammation were generally more focal than was the distribution of immune reactants. Most of the immune deposits were present in the walls of the blood vessels of myocardium (eight of 10) or pericardium (two of three). In one patient with Libman-Sacks endocarditis, immunoglobulin and complement components were present in the valve stroma and the vegetations. The immune deposits around epicardial nerve fibers in two patients with severe neurologic manifestations contained immunoglobulin E(IgE). In general, the most intense and widespread immune deposits were observed in patients with persistently increased serologic and clinical evidence of activity of their systemic disease. These results suggest a role for immune complex deposition in the pathogenesis of the cardiac lesions of SLE.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7004181     DOI: 10.1016/s0002-9343(80)80010-6

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  32 in total

1.  Diastolic impairment in asymptomatic systemic lupus erythematosus patients.

Authors:  E Astorri; P Fiorina; G A Contini; D Albertini; E Ridolo; P Dall'Aglio
Journal:  Clin Rheumatol       Date:  1997-05       Impact factor: 2.980

2.  Endomyocardial biopsies in the diagnosis of myocardial involvement in systemic lupus erythematosus.

Authors:  Y Gartshteyn; M Tamargo; S Fleischer; T Kapoor; J Li; A Askanase; R Winchester; L Geraldino-Pardilla
Journal:  Lupus       Date:  2020-01-10       Impact factor: 2.911

Review 3.  Systemic lupus erythematosus clinical issues.

Authors:  M B Stevens
Journal:  Springer Semin Immunopathol       Date:  1986

4.  Lupus myocarditis receiving the rituximab therapy-a monocentric retrospective study.

Authors:  Chrong-Reen Wang; Yi-Shan Tsai; Wei-Ting Li
Journal:  Clin Rheumatol       Date:  2018-01-03       Impact factor: 2.980

5.  Autoantibodies to types I and IV collagen and heart valve disease in systemic lupus erythematosus/antiphospholipid syndrome.

Authors:  José Pardos-Gea; Josefina Cortés-Hernández; Jesus Castro-Marrero; Eva Balada; José Ordi-Ros
Journal:  Clin Rheumatol       Date:  2017-03-10       Impact factor: 2.980

6.  Calorie restriction prevents the occlusive coronary vascular disease of autoimmune (NZW x BXSB)F1 mice.

Authors:  H Mizutani; R W Engelman; K Kinjoh; Y Kurata; S Ikehara; Y Matsuzawa; R A Good
Journal:  Proc Natl Acad Sci U S A       Date:  1994-05-10       Impact factor: 11.205

7.  Coronary artery bypass grafting in patients with systemic lupus erythematosus. Report of 2 cases.

Authors:  R G Rinaldi; J Carballido; B Betancourt; M Sartori; E A Almodóvar
Journal:  Tex Heart Inst J       Date:  1995

Review 8.  Heart involvement in systemic lupus erythematosus: a systemic review and meta-analysis.

Authors:  Junzhe Chen; Ying Tang; Mingsheng Zhu; Anping Xu
Journal:  Clin Rheumatol       Date:  2016-08-09       Impact factor: 2.980

9.  M mode and Doppler echocardiographic assessment of left ventricular diastolic function in primary antiphospholipid syndrome.

Authors:  N Coudray; D de Zuttere; O Blétry; J C Piette; B Wechsler; P Godeau; J C Pourny; Y Lecarpentier; D Chemla
Journal:  Br Heart J       Date:  1995-11

10.  Mitral regurgitation due to lupus endocarditis treated with valve replacement.

Authors:  F J Brennan; S E Ford; P M Ford; P A Morrin; G W Burggraf; T A Salerno
Journal:  Can Med Assoc J       Date:  1983-09-15       Impact factor: 8.262

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.